Emerald Advisers’s 10x Genomics TXG Stock Holding History

Emerald Advisers’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-18,140	Closed	-$1.62M	–	357
2020 Q2	$1.62M	Sell	18,140 -1,640	-8%	-$128K	0.07%	132
2020 Q1	$1.23M	Sell	19,780 -220	-1%	-$17.2K	0.07%	128
2019 Q4	$1.52M	Hold	20,000	–	–	0.06%	130
2019 Q3	$1.01M	Buy	+20,000	New	+$1.11M	0.05%	140

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMV

Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Advisers's TXG Position: Q3 2020 in Review

Emerald Advisers sold out of 10x Genomics (TXG) in Q3 2020, closing a stake of 18,140 shares — an estimated $1.62M sold.

Emerald Advisers first reported a position in TXG in Q3 2019 and held it in 4 quarters. The position peaked at $1.62M in Q2 2020. 218 funds tracked by Wall St. Rank hold TXG as of Q3 2020.

Emerald Advisers reported no remaining 10x Genomics position as of Q3 2020 after selling out during the quarter.
Emerald Advisers sold 18,140 10x Genomics shares in Q3 2020, an estimated $1.62M.
Emerald Advisers first reported a position in 10x Genomics in Q3 2019 and held it in 4 quarters.
Emerald Advisers's 10x Genomics position peaked at $1.62M in Q2 2020.
218 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2020.

Based on Emerald Advisers's 13F filing for Q3 2020, filed 28 Oct 2020.